Following the success of the first edition held in May 2025, the University of Catania and CoEHAR – Center of Excellence for the Acceleration of Harm Reduction – together with…
On May 30–31, 2025, the international scientific conference “TYPE 2 Diabetes in Internal Medicine Practice: Experience Sharings 1” was held in Catania, at the Romano Palace Hotel, bringing together over…
The University of Catania is proud to announce the upcoming international scientific conference titled "TYPE 2 Diabetes in Internal Medicine Practice: Experience Sharings 1", which will take place on May 30-31, 2025,…
On Saturday 16th November, Prof. Riccardo Polosa joined the 2024 Annual Cardiorenal, Obesity & Metabolic Health Summit held in Fujairah (UAE) to deliver an oral presentation on diabetes, smoking cessation…
Researchers from the CoEHAR at the University of Catania, together with international experts from the DiaSmokeFree Working Group, aimed to answer these questions: what could be the effects of smoking cessation on the efficacy and safety of antidiabetic drugs? Could significant changes occur that would require a readjustment of pharmacological treatments?
The results were included in the review "Behavioural therapy for people with diabetes who smoke: a scoping review," published in the Journal of Primary Care and Community Health: it is now clear that persons living with diabetes are not the subject of targeted treatments and that there is ample room for progress. It seems that more structured and intensive therapies could benefit these persons in bidding farewell to cigarette smoking, while little is still known about the possible benefits of combining behavioral therapies and nicotine replacement pharmacological therapies.
GFN 2023 will start tomorrow at Varsavia. The 10th edition of the Global Forum on Nicotine, from 21 to 24 June, will host more events dedicated to harm reduction research. During this edition will be also the second meeting of SAB Diasmoke. Diabetologists and experts on THR signed the guidelines on the treatment of smokers with diabetes.
Ten of the world’s leading experts in diabetes addressed the issue of smoking harm in this vulnerable population in its clinical, medical, behavioral and sociological implications, in order to provide independent consultation and oversight to the development of smoking cessation / harm reduction guidelines for smokers with type 2 diabetes mellitus.
A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus
Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a pool of European researchers revealed a lack of data on the metabolic effects of smoking and smoking cessation in diabetes. Healthcare professionals should not assume that cessation of smoking will improve metabolic parameters in patients with diabetes.
